What to expect.
- GLP-1 receptor agonist that supports appetite regulation and fullness
- One of the most extensively studied agents in the GLP-1 class (STEP and SUSTAIN trial programs)
- Once-weekly subcutaneous injection
- Supports steadier blood sugar alongside weight management
- Prescribed and monitored by a physician as part of an individualized plan
Dr. Taylor's take
“Semaglutide is the GLP-1 most patients have heard of, and for good reason: it has one of the deepest clinical evidence bases in the class. I prescribe it after a full medical intake, start low, and titrate slowly to keep the early nausea manageable. Like any GLP-1, it works best paired with nutrition and activity changes, and I monitor patients throughout.”
Dr. Patrick Taylor, MD · Live Vital physician
About Semaglutide.
Also known as: Ozempic, Wegovy, Rybelsus
Semaglutide is a once-weekly injectable GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone the gut releases after eating that signals fullness and helps regulate blood sugar. Developed by Novo Nordisk, it is also known by the brand names Ozempic, Wegovy, and (as an oral tablet) Rybelsus.
In the STEP-1 trial, adults without diabetes taking semaglutide for weight management lost an average of roughly 15% of their body weight over 68 weeks, alongside lifestyle changes. Live Vital offers semaglutide as a physician-prescribed therapy after a complete medical intake with Dr. Taylor, with ongoing monitoring as part of your care. Outcomes vary by individual and are not guaranteed.
How it works
Semaglutide activates the GLP-1 receptor, which slows the rate at which the stomach empties, reduces appetite by signaling fullness to the brain, and improves the release of insulin in response to meals. Together these effects help people feel satisfied on less food and keep blood sugar steadier. It is a single-target therapy, acting on the GLP-1 pathway, which distinguishes it from dual-agonist medications like tirzepatide.
Who it may help.
- Adults working on weight management who want a well-studied GLP-1 option
- People with excess weight who also have blood-sugar concerns
- Those who prefer a once-weekly injection
- Patients who want a physician-supervised protocol with ongoing monitoring
What to expect, when.
Doses are increased gradually over the first weeks to reduce side effects, so many patients notice reduced appetite early, with more meaningful weight change building over several months of consistent use. In clinical trials, weight reduction continued through the 68-week study period. Individual results vary and depend on your health history, dose, and how your body responds under Dr. Taylor's supervision.
Dosing is not one-size-fits-all. Dr. Taylor personalizes your dose and schedule after your medical intake, and adjusts it as your protocol progresses.
Safety information.
Possible side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
- Abdominal discomfort
- Injection site reactions
Who should talk to us first
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy or breastfeeding
- Severe gastrointestinal disease
This information is educational and is not a substitute for medical advice. Every protocol requires a medical intake and physician approval, and outcomes vary by individual.
Standard with every plan.
Doctor-prescribed
Prescribed through Live Vital’s licensed clinical team.
Licensed US pharmacy
Prepared by a licensed US pharmacy and shipped to you.
Unlimited messaging
Reach our care team directly with questions at any time.